These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 82125)

  • 1. Aspirin and bleeding-time.
    Rajah SM; Penny A; Kester R
    Lancet; 1978 Nov; 2(8099):1104. PubMed ID: 82125
    [No Abstract]   [Full Text] [Related]  

  • 2. The enigma of aspirin.
    Parkin JD
    Aust N Z J Med; 1987 Apr; 17(2):192-4. PubMed ID: 3304245
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of prostacyclin and platelet thromboxane A2 after low-dose aspirin.
    Preston FE; Whipps S; Jackson CA; French AJ; Wyld PJ; Stoddard CJ
    N Engl J Med; 1981 Jan; 304(2):76-9. PubMed ID: 7003384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of prostacyclin and platelet thromboxane A2 by aspirin.
    N Engl J Med; 1981 May; 304(19):1173-5. PubMed ID: 7012620
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of prostacyclin and thromboxane A2 in the regulation of platelet behaviour.
    Moncada S
    Mater Med Pol; 1980; 12(3):207-12. PubMed ID: 7019591
    [No Abstract]   [Full Text] [Related]  

  • 6. Maximal blockade of TxA2 without compromised PGI2 formation; a superior profile of the TxA2 receptor blocking drug GR32191 over aspirin.
    Lumley P; Keery RJ; Wharton KA; White BP; Watts IS
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21B():603-6. PubMed ID: 1825385
    [No Abstract]   [Full Text] [Related]  

  • 7. [Non-steroid inflammatory drugs in the prevention of myocardial infarction].
    Basista M; Kostka-Trabka E
    Pol Tyg Lek; 1983 Dec 19-26; 38(51-52):1645-8. PubMed ID: 6382207
    [No Abstract]   [Full Text] [Related]  

  • 8. Platelets and the vessel wall: how much aspirin?
    Pareti FI; D'Angelo A; Mannucci PM; Smith JB
    Lancet; 1980 Feb; 1(8164):371-2. PubMed ID: 6101829
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetics of enteric-coated aspirin and inhibition of platelet thromboxane A2 and vascular prostacyclin generation in humans.
    Cerletti C; Marchi S; Lauri D; Domanin M; Lorenzi G; Urso R; Dejana E; Latini R; de Gaetano G
    Clin Pharmacol Ther; 1987 Aug; 42(2):175-80. PubMed ID: 3301151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of low-dose aspirin on platelet aggregation and the biosynthesis of PGI2 and TXA2 in patients with coronary heart disease].
    Gao SW; Chen ZJ; Tao SQ
    Zhonghua Nei Ke Za Zhi; 1987 Apr; 26(4):209-12, 255. PubMed ID: 3308356
    [No Abstract]   [Full Text] [Related]  

  • 11. Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction.
    De Caterina R; Giannessi D; Bernini W; Gazzetti P; Michelassi C; L'Abbate A; Donato L; Patrignani P; Filabozzi P; Patrono C
    Am J Cardiol; 1985 Feb; 55(5):589-90. PubMed ID: 3969908
    [No Abstract]   [Full Text] [Related]  

  • 12. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin.
    Clarke RJ; Mayo G; Price P; FitzGerald GA
    N Engl J Med; 1991 Oct; 325(16):1137-41. PubMed ID: 1891022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological action on the thromboxane and prostacyclin balance in the body].
    Lakin KM; Makarov VA; Novikova NV; Tret'iak VM; Rukazenkov IuE
    Farmakol Toksikol; 1984; 47(2):67-79. PubMed ID: 6425078
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostaglandins and angioplasty. An experimental study in canine arteries.
    Zollikofer CL; Cragg AH; Einzig S; Castaneda-Zuniga WR; Castaneda F; Rysavy JA; Bruhlmann WF; Shebuski RJ; Amplatz K
    Radiology; 1983 Dec; 149(3):681-5. PubMed ID: 6227930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin as an antithrombotic medication.
    Marcus AJ
    N Engl J Med; 1983 Dec; 309(24):1515-7. PubMed ID: 6358887
    [No Abstract]   [Full Text] [Related]  

  • 16. Aspirin: A paradoxical effect on bleeding-time.
    O'Grady J; Moncada S
    Lancet; 1978 Oct; 2(8093):780. PubMed ID: 80698
    [No Abstract]   [Full Text] [Related]  

  • 17. Dose- and time-dependent antiplatelet effects of aspirin.
    Perneby C; Wallén NH; Rooney C; Fitzgerald D; Hjemdahl P
    Thromb Haemost; 2006 Apr; 95(4):652-8. PubMed ID: 16601836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A2 receptor and synthase inhibitor, in healthy subjects.
    Guth BD; Narjes H; Schubert HD; Tanswell P; Riedel A; Nehmiz G
    Br J Clin Pharmacol; 2004 Jul; 58(1):40-51. PubMed ID: 15206991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights into the inhibition of platelet activation by omega-3 polyunsaturated fatty acids: beyond aspirin and clopidogrel.
    Cohen MG; Rossi JS; Garbarino J; Bowling R; Motsinger-Reif AA; Schuler C; Dupont AG; Gabriel D
    Thromb Res; 2011 Oct; 128(4):335-40. PubMed ID: 21621252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of prostacycline, thromboxane A2 and prostaglandins in platelet aggregation (author's transl)].
    Herman AG
    Rev Med Brux; 1981 Mar; 2(3):251-7. PubMed ID: 7015444
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.